According to Precedence Research, the global cancer therapeutics market size is expected to more than double to $469.38 billion by 2034 from $212.58 billion in 2025.
Oncology is the single most lucrative industry in all of healthcare. Cancer drugs consistently generate more revenue than treatments for any other condition. Many of these therapies are designed for long-term use, and their high cost, often exceeding $100,000 per patient per year.
The United States holds the largest share of the global cancer therapeutics market—over 36% as of 2024.
This is due to a few factors: a high prevalence of cancer diagnoses, early access to new and experimental treatments, and the presence of major pharmaceutical companies. The U.S. healthcare system also permits higher drug prices compared to other countries, which significantly increases market value.
What the current market is focused on:
- Immunotherapy. Therapies that boost the patient’s own immune system to target cancer.
- Targeted therapies. Drugs that interfere with specific molecules involved in tumor growth, such as tyrosine kinase inhibitors or hormone blockers.
- CAR-T cell therapy. Reprogramming a patient’s T-cells to attack cancer cells; promising, but currently extremely expensive and labor-intensive.
- Monoclonal antibodies. Lab-created molecules that can bind to cancer cells and flag them for destruction.
- Antibody-drug conjugates (ADCs). Combining targeting antibodies with chemo-like agents to deliver toxic payloads directly to cancer cells.
- Precision medicine. Using genetic and molecular profiling to design tailored treatment plans for individual patients.
- mRNA cancer vaccines. Similar to COVID-19 vaccines but engineered to provoke an immune response against specific tumor proteins.
- Artificial intelligence tools. Used to predict tumor progression, assist in early detection, or optimize drug combinations.
Why is the investment so massive?
- High treatment costs. Newer therapies can cost between $100,000–$500,000+ per patient per year.
- Longer treatment timelines. Many therapies are not curative, but rather chronic, requiring repeated or lifelong use.
- Rising global cancer rates. Lifestyle, environmental, and demographic changes are pushing cancer diagnoses higher every year.
- Patent-protected drugs. Pharmaceutical companies are incentivized to develop expensive therapies that can be sold exclusively for years.
- Government and private funding. Enormous capital is being poured into cancer research from both public health budgets and private biotech investors.
- Combination therapies. Many patients now receive multiple drugs at once or in sequence, multiplying costs and complexity.
Most of the cancer therapies currently in development are designed to target a single molecular pathway: a specific protein, gene mutation, or signaling mechanism believed to be driving tumor growth.
While this narrow targeting can sound precise, it often fails to account for the complex, adaptive nature of cancer. Tumors rarely rely on just one pathway. Instead, they use multiple systems to survive, grow, and resist treatment.
So when one pathway is blocked, cancer cells can often bypass it by activating another. This is one reason why many targeted therapies show only modest benefits, especially when used alone.
This single-target approach also tends to come with high costs and limited durability. A patient might spend hundreds of thousands of dollars per year on a drug that extends survival by only a few months. And because tumors can evolve resistance quickly, these treatments often need to be combined with others, multiplying cost, side effects, and complexity. In many cases, what starts as a “targeted” solution becomes part of a prolonged, multi-drug management strategy, not a path toward recovery.
It’s a complicated issue. Financial investment is important because we do need to give companies and researchers incentives to develop new therapies and explore innovative options. However, when profit becomes the primary driver, it can skew priorities.
Ultimately, keeping patients on long-term treatments is the most profitable model for drug companies. A one-time cure generates far less revenue than a therapy that must be taken indefinitely.
Unfortunately, we are investing an enormous amount of money into building a system that manages cancer rather than one that heals patients from it. The focus has shifted toward disease control, stabilizing tumors, delaying progression, and extending survival through prolonged drug regimens.
The approach is starting to resemble how we treat conditions like type 2 diabetes or high blood pressure. In both cases, patients are often placed on long-term medications that help manage symptoms or maintain lab values within a certain range, but do not address the root cause.
Rather than reversing the disease through lifestyle, balancing hormones, resolving inflammation, improving immune function, nutrition, metabolic therapy, etc., the emphasis stays on keeping numbers in check with drugs.
I always try to share inexpensive cancer therapies, because there are many that have been well-studied and show promise, yet remain overlooked or dismissed simply because they aren’t profitable. Decades of research support the benefits of metabolic, nutritional, and hormonal interventions, but they do not receive any attention in mainstream oncology.
I say it all the time, but cancer is a SYSTEMIC disease.The entire body cooperates to create the internal conditions that allow cancer to develop. This is why a single-target drug will never be enough.
Some alternative, inexpensive options:
- Repurposed drugs (aspirin, cyproheptadine, selegiline, naltrexone, doxycycline)
- Hormones: progesterone & pregnenolone therapy
- High dose vitamin C IV
- Nutritional therapy: high dose thiamine, niacinamide, biotin, magnesium, vitamin D, vitamin E, etc.
- Thyroid therapy
- Ozone therapy
- Carbon dioxide therapy
- Glycine
- Emotional work
I’m hopeful for a cancer care model that focuses on true resolution, not just disease management: nutrition, hormone balance, metabolic support, emotional healing, and inexpensive therapies. A system that treats the person, not the tumor.